XML 49 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisition of EGEN Assets (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jun. 16, 2017
Jun. 20, 2014
Dec. 31, 2016
Jun. 20, 2014
Sep. 30, 2018
Jun. 30, 2018
Sep. 30, 2017
Jun. 30, 2017
Dec. 31, 2016
Sep. 30, 2018
Sep. 30, 2017
Dec. 31, 2017
Dec. 31, 2016
Asset impairment charges, total             $ 2,500,000            
Business Combination, Consideration Transferred, Liabilities Incurred         $ 9,000,000 $ 13,100,000 12,500,000 $ 13,800,000          
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability         4,100,000   1,300,000     $ (3,567,671)      
Assets         40,911,954         40,911,954   $ 47,514,433  
Finite-lived intangible assets, net, ending balance         625,121         625,121   795,608  
Purchase Agreement [Member]                          
Finite-lived intangible assets, net, ending balance         625,121         625,121   795,608  
Finite-lived intangible assets, accumulated amortization         966,093         966,093   795,606  
IPR&D Drug Technology Platforms [Member]                          
Asset impairment charges, total     $ 1,400,000           $ 1,400,000        
EGEN Inc [Member]                          
Potential future earn-out payments   $ 30,400,000   $ 30,400,000               24,400,000  
Payments to Acquire Businesses, Gross       $ 3,000,000                  
Stock issued during period, shares, acquisitions       193,728                  
Number of common stock issued or issuable 47,862                        
Business Combination, Consideration Transferred, Liabilities Incurred   13,900,000       $ 13,100,000   $ 13,800,000   9,000,000 $ 12,500,000 $ 12,500,000 $ 13,200,000
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability         4,114,995   1,246,151     3,567,671 670,172    
Goodwill, acquisition                   2,000,000      
EGEN Inc [Member] | Purchase Agreement [Member]                          
Gain (Loss) from Change in Fair Value of Earn out Milestone Liability         4,500,000                
Finite-lived intangible assets acquired                   $ 1,600,000      
Finite-lived intangible asset, useful life                   7 years      
Amortization expense         56,829   170,487     $ 56,829 170,487    
EGEN Inc [Member] | IPR&D Drug Technology Platforms [Member]                          
Indefinite lived intangible assets                   24,200,000      
EGEN Inc [Member] | Ovarian Cancer [Member]                          
Potential future earn-out payments         12,400,000         12,400,000      
Initial assets value         6,900,000         6,900,000      
Assets         2,400,000         2,400,000      
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]                          
Potential future earn-out payments         $ 12,000,000         $ 12,000,000      
Asset impairment charges, total             $ 6,900,000       $ 9,400,000    
EGEN Inc [Member] | Maximum [Member]                          
Total purchase price for the asset acquisition       $ 44,400,000                  
Potential future earn-out payments   $ 30,400,000   $ 30,400,000